Breakthrough Collaboration: Hanlim Pharma Partners with Invion for GBM Treatment

Invion Limited (ASX: IVX) has entered a significant collaboration with South Korean pharmaceutical giant, Hanlim Pharma Co., Ltd., to develop INV043, a potential treatment for glioblastoma multiforme (GBM), a fatal brain cancer. The partnership aims to conduct Proof-of-Concept studies, led by Professor Sin-Soo Jeun at Seoul St. Mary’s Hospital, a renowned medical institution. Hanlim, known for its substantial revenue and workforce, recognizes INV043's potential efficacy against various cancers.

The collaboration targets both diagnostic and therapeutic aspects of GBM treatment. With Hanlim's investment in Photodynamic Therapy (PDT) development and Invion's supply of Photosoft™ compounds, the venture anticipates significant progress. This endeavor holds promise for addressing the critical need for effective GBM treatments, with potential commercialization opportunities in global markets.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com